10-QPeriod: Q2 FY2023

DEXCOM INC Quarterly Report for Q2 Ended Jun 30, 2023

Filed July 27, 2023For Securities:DXCM

Summary

DexCom, Inc. reported a strong second quarter of 2023, demonstrating robust financial performance with significant year-over-year growth in revenue and profitability. The company saw revenue increase by 25% to $871.3 million, driven by higher sales volumes of its disposable sensors, reflecting continued global customer base expansion. Profitability also showed substantial improvement, with operating income up 66% and net income more than doubling to $115.9 million. This was supported by a gross profit increase of 22% and effective management of operating expenses, despite higher SG&A costs primarily due to increased headcount and marketing initiatives. The company ended the quarter with a healthy cash position of $3.64 billion, indicating strong financial health and ample resources for future growth initiatives. Looking ahead, DexCom anticipates continued growth driven by the increasing incidence of diabetes, demand for digital health technologies, and expansion into new markets and patient populations. However, investors should remain aware of ongoing patent litigation with Abbott and potential pricing pressures from third-party payors. The company's strategic investments in manufacturing capacity, particularly in Malaysia and Ireland, are expected to support future demand.

Financial Highlights

52 data points
Beta

Revenue

$871.30M

62.7% Gross Margin

Net Income

$115.90M

13.3% Net Margin

EPS (Diluted)

$0.28

Total Assets

$6.82B

Cash & Equivalents

$1.19B

Free Cash Flow

$131.30M

Financial Statements
Beta
Revenue$871.30M
Cost of Revenue$324.90M
Gross Profit$546.40M
R&D Expenses$119.30M
SG&A Expenses$299.00M
Operating Expenses$418.30M
Operating Income$128.10M
Interest Expense$5.00M
Net Income$115.90M
EPS (Basic)$0.30
EPS (Diluted)$0.28
Shares Outstanding (Basic)386.70M
Shares Outstanding (Diluted)431.50M

Key Highlights

  • 1Revenue increased by 25% to $871.3 million in Q2 2023 compared to Q2 2022.
  • 2Net income saw a substantial increase of 128% to $115.9 million in Q2 2023.
  • 3Operating income grew by 66% to $128.1 million in Q2 2023.
  • 4Gross profit margin decreased slightly from 64.6% in Q2 2022 to 62.7% in Q2 2023, attributed to mix shifts and intangible asset amortization.
  • 5Selling, General, and Administrative (SG&A) expenses increased by 19% year-over-year, driven by higher compensation costs and marketing spend.
  • 6Research and Development (R&D) expenses decreased by 2% year-over-year, primarily due to lower third-party and consulting fees.
  • 7The company ended the quarter with $3.64 billion in cash, cash equivalents, and short-term marketable securities.

Frequently Asked Questions

The substantial 25% revenue growth to $871.3 million was primarily driven by an increase in sales volume of DexCom's disposable sensors, reflecting the continued expansion of its global customer base. This was partially offset by shifts in product and channel mix.

DexCom demonstrated significant improvements in profitability. Net income rose by 128% to $115.9 million, and operating income increased by 66% to $128.1 million in the second quarter of 2023 compared to the same period in 2022. This was supported by strong revenue growth and effective management of operating expenses.

DexCom maintains a strong liquidity position, ending the quarter with $3.64 billion in cash, cash equivalents, and short-term marketable securities. This provides ample financial flexibility for ongoing operations, strategic investments, and potential future opportunities.

Yes, DexCom is involved in ongoing patent infringement litigation with Abbott. A jury trial concerning breach of contract claims initiated by Abbott concluded with a verdict in July 2023. While Dexcom intends to vigorously defend its intellectual property, the outcome of this litigation remains uncertain and could potentially impact the company's financial condition.